Keros Therapeutics
KROS | NASDAQ
$10.03
-$0.27 (-2.62%)
At close: Nov 16, 2026, 4:00 PM ET
$10.18
+$0.15 (+1.50%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-2.62%
(1D)No price chart data available for 1D timeframe.
Rating
54
Fundamentals Strong
Market Sentiment Neutral
Moat None
Sector Rank #202/1021 (Top 20%)
Key Statistics
Market Data
Market Cap $373.33M
1D Range
9.91 10.74
52W Range
9.17 21.84
Valuation (TTM)
PE -2.85
PB 1.34
EV/EBITDA -2.04
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $20.00
Cash Flow
FCF Yield -12.9%
SBC Adj. FCF Yield -19.1%
SBC Impact -47.8%
Margins
Gross Margin 98.0%
Operating Margin -179.8%
FCF Margin -118.4%
Growth (CAGR)
Revenue 3Y | 5Y 1620.8% |
232.7%
Dil EPS 3Y | 5Y 40.0% |
17.7%
FCF 3Y | 5Y 136.3% |
42.6%
Returns
ROA -20.1%
ROE -21.9%
ROIC -24.6%
Financial Health
Net Cash
$244.35M
Current Ratio 18.14
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and...
Sector Healthcare
Industry Biotechnology
Employees 92
IPO Date Apr 8, 2020
Website www.kerostx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 5, 2026
EPS
$0.7
Beat +172.92%
YoY:
+488.89% REV
$40.01M
Beat +170.98%
YoY:
+180.53%Next Earnings
Mar 3, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$20.00
Upside
+99.40%
Buy (2)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove KROS